BlackRock Inc. increased its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 5.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,067,094 shares of the biopharmaceutical company’s stock after purchasing an additional 202,306 shares during the period. BlackRock Inc. owned 6.53% of Dynavax Technologies worth $62,023,000 at the end of the most recent quarter.
Several other hedge funds have also recently modified their holdings of the stock. Wells Fargo & Company MN grew its stake in shares of Dynavax Technologies by 9.2% during the first quarter. Wells Fargo & Company MN now owns 45,516 shares of the biopharmaceutical company’s stock worth $903,000 after purchasing an additional 3,834 shares in the last quarter. Creative Planning boosted its stake in Dynavax Technologies by 2.6% in the second quarter. Creative Planning now owns 235,105 shares of the biopharmaceutical company’s stock valued at $3,585,000 after acquiring an additional 5,857 shares in the last quarter. New York State Common Retirement Fund boosted its stake in Dynavax Technologies by 10.8% in the first quarter. New York State Common Retirement Fund now owns 65,700 shares of the biopharmaceutical company’s stock valued at $1,304,000 after acquiring an additional 6,400 shares in the last quarter. Guggenheim Capital LLC boosted its stake in Dynavax Technologies by 7.2% in the first quarter. Guggenheim Capital LLC now owns 112,278 shares of the biopharmaceutical company’s stock valued at $2,228,000 after acquiring an additional 7,522 shares in the last quarter. Finally, Alps Advisors Inc. boosted its stake in Dynavax Technologies by 11.2% in the second quarter. Alps Advisors Inc. now owns 90,375 shares of the biopharmaceutical company’s stock valued at $1,378,000 after acquiring an additional 9,103 shares in the last quarter. Hedge funds and other institutional investors own 82.02% of the company’s stock.
NASDAQ DVAX opened at $11.29 on Friday. The company has a debt-to-equity ratio of 0.76, a current ratio of 8.87 and a quick ratio of 8.67. Dynavax Technologies Co. has a 1 year low of $10.35 and a 1 year high of $23.85. The firm has a market capitalization of $776.43 million, a price-to-earnings ratio of -6.53 and a beta of 0.30.
Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Monday, August 6th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Dynavax Technologies had a negative net margin of 8,570.06% and a negative return on equity of 72.31%. The company had revenue of $1.25 million during the quarter, compared to analyst estimates of $1.88 million. During the same quarter in the prior year, the company earned ($0.41) EPS. The business’s revenue was up 1094.3% on a year-over-year basis. On average, sell-side analysts anticipate that Dynavax Technologies Co. will post -2.39 EPS for the current fiscal year.
Several research firms have issued reports on DVAX. Cantor Fitzgerald restated a “buy” rating and issued a $30.00 price objective on shares of Dynavax Technologies in a research note on Monday, August 6th. ValuEngine downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Monday, July 30th. BidaskClub upgraded shares of Dynavax Technologies from a “strong sell” rating to a “sell” rating in a research note on Thursday. Finally, Zacks Investment Research upgraded shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, August 9th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $27.50.
Dynavax Technologies Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Featured Article: Cash Flow Analysis in Stock Selection
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.